UEEC United Health Products

United Health Products Submits Full FDA PMA Application

United Health Products Submits Full FDA PMA Application

MOUNT LAUREL, NJ, March 21, 2024 (GLOBE NEWSWIRE) -- via -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s FDA Premarket Approval application process.  

The company confirms that it has submitted via the FDA eSTAR portal its Premarket Approval (PMA) application for its absorbable hemostatic gauze, which will now be reviewed by the FDA and Health Canada. Information on the FDA review process for PMA applications can be found on the FDA website at:

There can be no assurance that the company’s PMA or Health Canada applications will be approved.

About United Health Products -- UHP develops, manufactures and markets HemoStyp™, a patented Neutralized Regenerated Cellulose hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and emergency medicine markets, and is seeking approval to access the human surgical market. 

For more information on UHP visit the company’s new website:  or contact the company at  .

The company can also be reached by phone or text message at 475.755.1005

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.



EN
21/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on United Health Products

 PRESS RELEASE

United Health Products Provides Update on Clinical Study Process

United Health Products Provides Update on Clinical Study Process MT. LAUREL, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s planned clinical study.  As previously disclosed, United Health Products is conducting a clinical trial of its CelluSTAT Hemostatic Gauze product (formerly branded as HemoStyp) in response to the FDA’s request for additional clinical data. On November 29th, the company submitted to the FDA an Investigational Device Exemption application (IDE), the approval of which is a precondition to en...

 PRESS RELEASE

United Health Products Provides Update on FDA PMA Application

United Health Products Provides Update on FDA PMA Application MOUNT LAUREL, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s FDA Premarket Approval (PMA) application process. Following the company’s August 15, 2024 submission of its Submission Issue Request (SIR) to the FDA which responded to certain questions in the FDA’s June 18 letter and described the company’s approach to addressing certain FDA-identified deficiencies in its PMA application, the company held a videoconference with the FDA on October 29. The ...

 PRESS RELEASE

United Health Products Submits Response Letter to FDA

United Health Products Submits Response Letter to FDA MT. LAUREL, NJ, Aug. 19, 2024 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s FDA Premarket Approval (PMA) application process.   Following the company’s March 21 submission of its PMA application and the FDA’s June 18 “Deficiencies Letter” to the company listing certain questions and comments on various elements of the application, on August 15, UHP submitted a Submission Issue Request to the FDA responding to certain questions and detailing its approach to addressing certain...

 PRESS RELEASE

United Health Products Submits Full FDA PMA Application

United Health Products Submits Full FDA PMA Application MOUNT LAUREL, NJ, March 21, 2024 (GLOBE NEWSWIRE) -- via -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s FDA Premarket Approval application process.   The company confirms that it has submitted via the FDA eSTAR portal its Premarket Approval (PMA) application for its absorbable hemostatic gauze, which will now be reviewed by the FDA and Health Canada. Information on the FDA review process for PMA applications can be found on the FDA website at: There can be no assurance that the c...

 PRESS RELEASE

United Health Products Reports on FDA Application Status

United Health Products Reports on FDA Application Status MESQUITE, NV, Jan. 19, 2024 (GLOBE NEWSWIRE) -- via – United Health Products (UEEC) reports today on the receipt and review of final reports on product sterilization and stability testing for its hemostatic gauze. As previously disclosed, UHP has been working with external packaging and sterilization service providers to complete various required tests for its Premarket Approval application. The reported data received this week on the efficacy of the proposed radiation sterilization protocol were well within acceptable bioburden le...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch